History
Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. [3] [4] In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System, in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation [5] and Animas Corporation [6] as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment. [7]
During February 2009, Dexcom received approval for the Seven Plus Continuous Glucose Monitor, its new continuous glucose monitoring system, from the FDA. This product received a CE mark in November 2009. In 2013, development work for integration with Insulet was discontinued. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its forthcoming G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. [8] The G5 was approved in 2016 by the FDA for use as a standalone device, while the G6 gained approval in 2018. [9]
Dexcom's first G-series CGM, the G4 Platinum, received a CE mark [10] and FDA approval in 2012 [11] for adults ages 18 and over. This device improved hypoglycemic accuracy by 30%. [11] It also offered a longer range of transmission between the sensor and receiver, as well as a color LCD. [11] The G4 Platinum was approved by the FDA for use in patients ages 2–17 in February 2014. [12] Dexcom received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the sharing of CGM data with up to five other people using the "Share" and "Follow" smartphone apps. [13]
The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device, [14] the G5 has Bluetooth integrated into its transmitter, enabling it to send data to a mobile device. [15] This allows for use of the device without the standalone receiver. The Dexcom G5 received a CE mark in September 2015. [16]
Dexcom is listed on the Nasdaq Global Select Market stock exchange under the ticker symbol DXCM. On April 20, 2020, Dexcom became a component of the Nasdaq-100, replacing American Airlines Group in the index. [17]
The Dexcom G7 was approved in December 2022 by the FDA for use as a standalone device and is the most accurate currently approved CGM in the U.S. [18]
In a 2024 interview, Jake Leach, Dexcom's COO, stated his belief that while noninvasive glucose monitoring is a "beautiful concept" current technology doesn't match the accuracy of existing invasive CGMs. He emphasizes that high CGM accuracy is crucial, even for non-insulin users, to avoid misdiagnosis of metabolic conditions. While Dexcom has explored new noninvasive approaches through its venture arm, nothing has yet met its standards for a viable product. [19]
In October 2024, Time Magazine named Dexcom Stelo's over-the-counter glucose monitor as one of the best inventions of the year. [20]
This page is based on this
Wikipedia article Text is available under the
CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
US$3.62 billion (2023)
US$2.07 billion (2023)